Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 26 peer-reviewed journal articles Updated
Dermatology

Standard Care and Treatment Options for LAD

At a Glance

Dapsone is usually the first treatment for linear IgA dermatosis, but G6PD testing and ongoing blood monitoring are essential because the medicine can damage red blood cells. Other medicines or specialist therapies may be considered if dapsone is unsafe or ineffective.

Because Linear IgA Dermatosis (LAD) is a rare condition, there are no large-scale clinical trials to dictate treatment. Instead, doctors rely on international consensus guidelines and expert experience to manage the disease [1][2]. The goal of treatment is to stop new blisters from forming and allow the skin to heal while minimizing side effects [3].

First-Line Treatment: Dapsone

For most patients, the primary treatment is dapsone, an oral medication that specifically targets the neutrophils (white blood cells) responsible for the blistering in LAD [2][4].

  • Dosing: Doctors usually start with a low dose and gradually increase it (titrate) until the blisters stop appearing. In children, a common starting dose is around 0.5 mg/kg per day [5]. In adults, doctors may start at 50 mg per day or roughly 1 mg/kg per day [6][7]. These dosing numbers are individualized clinical examples, not amounts you should ever start or adjust yourself.
  • The “Bridge”: Because dapsone can take time to reach its full effect, doctors sometimes consider systemic corticosteroids (like prednisone) as a short-term adjunct [8]. These act as a “bridge” to quickly calm inflammation while the dapsone begins to work, but they are an individualized option with their own risks, not an automatic requirement [8][9].

Mandatory Safety Check: G6PD Testing

Before you or your child takes the first dose of dapsone, you must have a blood test for G6PD enzyme deficiency [10][11].

  • The Risk: Dapsone creates “oxidative stress” in the blood. Most people have an enzyme called G6PD that protects their red blood cells from this stress. If you are deficient in this enzyme, dapsone can cause hemolysis—a dangerous condition where your red blood cells burst [11][12]. Note that even a normal G6PD result does not entirely eliminate the risk.
  • Ongoing Monitoring: Your care team will establish a clinician-directed baseline and follow-up plan for blood tests [13]. Your care team will watch for:
    • Hemolytic Anemia: A drop in red blood cells that can cause pale skin and fatigue [13][14].
    • Methemoglobinemia: A condition where the blood carries less oxygen. Symptoms include headache, shortness of breath, or a bluish tint to the lips and nails (cyanosis) [14][15].
    • Agranulocytosis: A rare but serious drop in infection-fighting white blood cells [16].
  • Dapsone Hypersensitivity Syndrome: Seek urgent care if you develop fever, widespread rash, facial or lymph-node swelling, dark urine, or jaundice in the first weeks of treatment, as these may signal a serious reaction.

Managing Drug-Induced LAD

If a medication like vancomycin triggered the LAD, a suspected culprit drug should be stopped promptly by your prescribing clinician or acute-care team [17][18]. Contact your prescriber urgently and do not stop essential medicines on your own or re-challenge yourself.

  • Recovery: Many patients see their skin begin to clear within days of safely stopping the trigger, and some may not need any other treatment [19][17].
  • Delayed Reactions: Be aware that blisters can sometimes continue to appear for a few days even after the drug is stopped, particularly if there are other health issues like kidney strain that slow down how fast the body clears the medication [20][21].

Options for Resistant (Refractory) LAD

If dapsone cannot be used or isn’t working well enough, your doctor may explore other options:

  • Sulfonamides: Drugs like sulfapyridine or sulfasalazine work similarly to dapsone and can be very effective, especially in children [22][23].
  • Antibiotic Combinations: Some patients respond to a combination of tetracycline and nicotinamide (a form of Vitamin B3), which has anti-inflammatory properties [3][24].
  • Advanced Therapies: For very severe or stubborn cases, specialists may use specialized off-label treatments, such as Rituximab (a biologic that depletes specific CD20-positive B cells) or IVIG (intravenous immunoglobulin) [25][3][26].

Always ensure that any suspected drug triggers are clearly documented in your medical records as an allergy to prevent accidental re-exposure in the future [17].

Common questions in this guide

What is usually the first treatment for linear IgA dermatosis?
Dapsone is usually the first-line treatment for LAD because it helps reduce the immune cells that drive blistering. Clinicians typically start with a low dose and increase it gradually while monitoring how you respond.
Why do I need a G6PD test before taking dapsone?
G6PD testing checks whether your red blood cells have enough of an enzyme that protects them from damage. If you have G6PD deficiency, dapsone can cause red blood cells to break down, so the result helps your clinician assess whether dapsone is safe; even a normal result does not remove all risk.
What blood tests are needed during dapsone treatment for LAD?
Your care team may arrange baseline and follow-up blood tests, including a complete blood count and reticulocyte count, to look for blood-cell problems. The exact schedule is individualized, especially during the first weeks of treatment.
What warning signs should I watch for while taking dapsone?
Seek urgent medical help for severe fatigue, shortness of breath, headache, blue lips or nails, dark urine, yellowing of the skin or eyes, fever, a widespread rash, facial swelling, or swollen lymph nodes. These symptoms can signal problems such as reduced oxygen delivery, red blood cell breakdown, or a serious drug reaction.
How is drug-induced LAD treated if vancomycin or another medicine is the trigger?
The prescribing clinician or acute-care team should promptly assess whether the suspected medicine can be stopped safely; do not stop an essential medicine or restart the suspected trigger on your own. Blisters may begin improving within days, but new blisters can continue briefly after the drug is stopped, and the trigger should be clearly documented as a medication allergy.
What are the alternatives if dapsone does not work or cannot be used?
Clinicians may consider sulfapyridine or sulfasalazine, and some patients respond to tetracycline combined with nicotinamide. For severe or persistent LAD, specialists may consider off-label treatments such as rituximab or intravenous immunoglobulin.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Linear IgA dermatosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Have I (or has my child) received a quantitative G6PD test, and what were the results?
  2. 2.What is the specific schedule for blood tests (CBC and reticulocyte count) during the first few weeks of dapsone treatment?
  3. 3.If we need to use steroids as an adjunct, what is the plan for tapering them off safely?
  4. 4.If this is drug-induced, should I have this medication listed as a formal allergy in my medical records to prevent future exposure?
  5. 5.What symptoms of methemoglobinemia (like fatigue or shortness of breath) should I be watching for at home?

References

References (26)
  1. 1

    S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and Venereology.

    Caux F, Patsatsi A, Karakioulaki M, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(6)):1006-1023 doi:10.1111/jdv.19880.

    PMID: 38421060
  2. 2

    Management Options for Linear Immunoglobulin A (IgA) Bullous Dermatosis: A Literature Review.

    Khan M, Park L, Skopit S

    Cureus 2023; (15(3)):e36481 doi:10.7759/cureus.36481.

    PMID: 37090290
  3. 3

    Clinical characteristics and treatment outcomes of linear IgA bullous dermatosis.

    Mar K, Landells F, Khalid B, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025; (23(5)):576-585 doi:10.1111/ddg.15644.

    PMID: 40018881
  4. 4

    Anti-NC16A IgA from Patients with Linear IgA Bullous Dermatosis Induce Neutrophil-Dependent Subepidermal Blistering in Mice.

    Jing K, Jordan TJM, Li N, et al.

    The Journal of investigative dermatology 2024; (144(1)):24-32.e1 doi:10.1016/j.jid.2023.05.027.

    PMID: 37437774
  5. 5

    Linear IgA bullous dermatosis of childhood.

    Nasri J, Jungo P, Blickenstorfer M, et al.

    Dermatology online journal 2022; (28(5)) doi:10.5070/D328559270.

    PMID: 36809139
  6. 6

    Linear IgA Bullous Dermatosis in an Elderly Patient Following Meloxicam and Candesartan Use: A Case Report.

    Albyali S, Alhedaithi N, Alqahtani R, et al.

    Cureus 2025; (17(12)):e99054 doi:10.7759/cureus.99054.

    PMID: 41527635
  7. 7

    Topical imiquimod-induced linear IgA bullous dermatosis.

    Tadiotto Cicogna G, Ferranti M, Vaccari D, Alaibac M

    BMJ case reports 2019; (12(7)) doi:10.1136/bcr-2019-230037.

    PMID: 31326906
  8. 8

    Consensus on the treatment of autoimmune bullous dermatoses: dermatitis herpetiformis and linear IgA bullous dermatosis - Brazilian Society of Dermatology.

    Vale ECSD, Dimatos OC, Porro AM, Santi CG

    Anais brasileiros de dermatologia 2019; (94(2 Suppl 1)):48-55 doi:10.1590/abd1806-4841.2019940208.

    PMID: 31166403
  9. 9

    Idiopathic linear IgA bullous dermatosis treated with prednisone.

    Garces CC, Salam MF, Nohomovich B, Varghese MT

    BMJ case reports 2021; (14(5)) doi:10.1136/bcr-2021-242237.

    PMID: 33980564
  10. 10

    Case report: Dupilumab: a promising treatment option for adult linear IgA bullous dermatosis with severe pruritus.

    Wang L, Peng J, Chen J

    Frontiers in immunology 2024; (15()):1409556 doi:10.3389/fimmu.2024.1409556.

    PMID: 39161758
  11. 11

    Molecular Mechanisms of Drug-Induced Hemolysis in G6PD Deficiency: Mechanistic Insights.

    Paika S, Machini M, Parmar MS

    Oxidative medicine and cellular longevity 2025; (2025()):7041213 doi:10.1155/omcl/7041213.

    PMID: 40799291
  12. 12

    Hemolysis and Metabolic Lesion of G6PD Deficient RBCs in Response to Dapsone Hydroxylamine in a Humanized Mouse Model.

    Dziewulska KH, Reisz JA, Hay AM, et al.

    The Journal of pharmacology and experimental therapeutics 2023; (386(3)):323-330 doi:10.1124/jpet.123.001634.

    PMID: 37348965
  13. 13

    Diaminodiphenyl Sulfone-Induced Hemolytic Anemia and Alopecia in a Case of Linear IgA Bullous Dermatosis.

    Akasaka E, Kayo SJ, Nakano H, et al.

    Case reports in dermatology 2015; (7(2)):183-6 doi:10.1159/000438506.

    PMID: 26351428
  14. 14

    Clinical Indicators Suggesting Dapsone-Induced Methemoglobinemia in Dermatology Outpatients: A Pilot Retrospective Cohort Study.

    Mathews J, Thomas A, Lekshmi S P, et al.

    Cureus 2026; (18(6)):e111188 doi:10.7759/cureus.111188.

    PMID: 42333280
  15. 15

    Methaemoglobinaemia as an Alternative Diagnosis for Shortness of Breath: A Case Report.

    Thiri T, San SS, Lwin ZT

    Cureus 2025; (17(5)):e83525 doi:10.7759/cureus.83525.

    PMID: 40470439
  16. 16

    Development of a multivariate predictive model for dapsone adverse drug events in people with leprosy under standard WHO multidrug therapy.

    de Araujo ACGDS, Hacker MAV, Pinheiro RO, et al.

    PLoS neglected tropical diseases 2024; (18(1)):e0011901 doi:10.1371/journal.pntd.0011901.

    PMID: 38271456
  17. 17

    Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases.

    Garel B, Ingen-Housz-Oro S, Afriat D, et al.

    British journal of clinical pharmacology 2019; (85(3)):570-579 doi:10.1111/bcp.13827.

    PMID: 30511379
  18. 18

    Linear Immunoglobulin A (IgA) Bullous Dermatosis Mimicking Stevens-Johnson Syndrome.

    Park JS, Hamilton CD, Patel S, et al.

    Cureus 2022; (14(10)):e30309 doi:10.7759/cureus.30309.

    PMID: 36381872
  19. 19

    Vancomycin-induced bullous dermatosis: a rare case report.

    Sakkal N, Jazmati A, Alosman MA, et al.

    Annals of medicine and surgery (2012) 2023; (85(6)):3022-3025 doi:10.1097/MS9.0000000000000752.

    PMID: 37363561
  20. 20

    Vancomycin-induced linear IgA bullous dermatosis: associations.

    Gameiro A, Gouveia M, Tellechea O, Goncalo M

    Dermatology online journal 2016; (22(4)).

    PMID: 27617457
  21. 21

    Drug-Induced Linear IgA Bullous Dermatosis Emerging After Vancomycin Discontinuation in Renal Impairment: Management Amid Serious Infection.

    Peake KE, Chow EY

    Cureus 2025; (17(8)):e91255 doi:10.7759/cureus.91255.

    PMID: 41030698
  22. 22

    Childhood Linear IgA Dermatosis Successfully Treated with the Combination of Dapsone and Sulfasalazine.

    Kim AS, Sundnes O

    Case reports in dermatology 2025; (17(1)):185-190 doi:10.1159/000546155.

    PMID: 40475121
  23. 23

    Successful treatment of a case of idiopathic linear IgA bullous dermatosis with oral sulfasalazine.

    Yang Z, Liu ZH, Sun CQ, Shen H

    Dermatologic therapy 2020; (33(2)):e13210 doi:10.1111/dth.13210.

    PMID: 31895494
  24. 24

    Linear IgA bullous dermatosis: 32 years of experience.

    Atci T, Pehlivan Ulutas G, Güreler Sirkeci E, Küçükoğlu R

    Anais brasileiros de dermatologia 2025; (100(2)):277-282 doi:10.1016/j.abd.2024.03.015.

    PMID: 39665877
  25. 25

    Updates in the Diagnosis and Management of Linear IgA Disease: A Systematic Review.

    Shin L, Gardner JT, Dao H

    Medicina (Kaunas, Lithuania) 2021; (57(8)) doi:10.3390/medicina57080818.

    PMID: 34441024
  26. 26

    A String of Pearls: Linear Immunoglobulin A (IgA) Bullous Dermatosis in the Setting of Imipramine Use and Newly Diagnosed Ulcerative Colitis.

    Davis S, Altattan M, Abugharbyeh A, et al.

    Cureus 2023; (15(1)):e33448 doi:10.7759/cureus.33448.

    PMID: 36751220

This page explains treatment and medication safety for linear IgA dermatosis for informational purposes only and does not replace medical advice. Do not start, stop, or change dapsone or any other medicine without your clinician’s guidance.